SEARCH:   Advanced

Blood, 15 May 2008, Vol. 111, No. 10, pp. 5233-5241. Prepublished online as a Blood First Edition Paper on February 6, 2008; DOI 10.1182/blood-2007-12-128488. This Article Full Text (PDF) All Versions of this Article: blood-2007-12-128488v1 111/10/5233    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Roord, S. T.A. Articles by van Wijk, F. Search for Related Content PubMed PubMed Citation Articles by Roord, S. T.A. Articles by van Wijk, F. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted December 20, 2007 Accepted January 24, 2008 Autologous bone marrow transplantation in autoimmune arthritis restores immune homeostasis through CD4+CD25+ FOXP3+ regulatory T cells Sarah T.A. Roord, Wilco de Jager, Louis Boon, Nico Wulffraat, Anton Martens, Berent Prakken*, and Femke van Wijk Department of Pediatric Immunology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, Netherlands Bioceros B.V., Utrecht, Netherlands Department of Hematology, University Medical Center Utrecht, Wilhelmina Children's Hospital, Utrecht, Netherlands * Corresponding author; email: b.prakken{at}umcutrecht.nl. Despite the earlier use of potent immunosuppressive or cytostatic drugs and the recent emergence of biologicals as treatment for human Autoimmune Diseases (AID), some patients still remain unresponsive to treatment. To those severely ill patients autologous Bone Marrow Transplantation (aBMT) is applied as a last resource, leading to disease remission in a majority of patients. The underlying mechanism of action of aBMT is still largely unknown. Here, we showed that regulatory T cells (Tregs) play a role in the natural disease course of Proteoglycan Induced Arthritis (PGIA) and in disease remission by aBMT. ABMT led to an initial phase of rapid disease improvement corresponding with a relative increase in CD4+CD25+ T cells. At this time the CD4+CD25+ cells did not show an increase in Foxp3 expression yet and showed less potent suppression. After this initial improvement disease relapsed but stabilised at a level below the severity before aBMT. This second phase was actively regulated by potently suppressive CD4+CD25+Foxp3+ Tregs. This work provided further insight into the role of Tregs in restoration of the immune balance by aBMT and can open the way to explore therapeutical interventions to further improve treatment of AID and disease relapses. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: "Regulating" rheumatoid arthritis via autotransplantation Steven Z. Pavletic and Daniel H. Fowler Blood 2008 111: 4838-4839. [Full Text] [PDF] This article has been cited by other articles: C. Bouffi, F. Djouad, M. Mathieu, D. Noel, and C. Jorgensen Multipotent mesenchymal stromal cells and rheumatoid arthritis: risk or benefit? Rheumatology, October 1, 2009; 48(10): 1185 - 1189. [Abstract] [Full Text] [PDF] A. L. Putnam, T. M. Brusko, M. R. Lee, W. Liu, G. L. Szot, T. Ghosh, M. A. Atkinson, and J. A. Bluestone Expansion of Human Regulatory T-Cells From Patients With Type 1 Diabetes Diabetes, March 1, 2009; 58(3): 652 - 662. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020